
    
      EBV positive metastatic GC patients who failed to standard chemotherapy will receive therapy
      of single agent, PD-1 antibody, SHR-1210, 200mg, every 2 weeks. The primary endpoint is
      response rate. Secondary endpoint is progress free survival, overall survival, safety and
      quality of life. Using the Simon two-stage sample size calculation, the sample size is 19. We
      will collect tissue and blood sample for exploratory analysis, including PD-L1 stuatus, tumor
      mutation burden, et al.
    
  